TheBodyPro | Is it OK to leave anal HSIL untreated in our patients with HIV?
A recent study suggests that anal high-grade squamous intraepithelial lesions (HSIL) in HIV-positive men may regress without treatment. These findings challenge existing clinical approaches and encourage further discussion on screening protocols.
Why it matters
This research could lead to less invasive treatment strategies for patients living with HIV, potentially improving quality of life and reducing unnecessary medical interventions.
Most anal high-grade squamous intraepithelial lesions (HSIL) will regress without treatment, according to recently published study results from a cohort of French men who are living with HIV and who have sex with other men (MSM). The findings provide us with important nuance in the wake of the guideline-changing ANCHOR study, and hopefully will reignite a conversation about how best to approach anal cancer screening and treatment in patients living with HIV.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in